SCS Capital Management LLC Makes New $835,000 Investment in Gilead Sciences, Inc. $GILD

SCS Capital Management LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,609 shares of the biopharmaceutical company’s stock, valued at approximately $835,000.

Other hedge funds have also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC purchased a new stake in Gilead Sciences in the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC grew its holdings in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares during the period. Finally, Wilkerson Advisory Group LLC increased its stake in shares of Gilead Sciences by 54.2% during the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 78 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $138.36 on Monday. The firm’s 50 day moving average price is $130.11 and its 200-day moving average price is $136.44. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a market cap of $171.56 billion, a PE ratio of -51.82 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter last year, the firm earned $2.01 earnings per share. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on GILD shares. Morgan Stanley lowered their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday. Rothschild & Co Redburn lowered their price objective on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Needham & Company LLC reiterated a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can’t import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares of the company’s stock, valued at $77,160,851.23. This represents a 2.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 51,000 shares of company stock valued at $6,568,860. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.